Efficacy analysis and prediction in phase II clinical trials of non-small cell Lung Cancer
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
Glavni autor: | Hoque, Ismoth Ara |
---|---|
Daljnji autori: | Azam, Faruque |
Format: | Disertacija |
Jezik: | English |
Izdano: |
Brac University
2024
|
Teme: | |
Online pristup: | http://hdl.handle.net/10361/23164 |
Similar Items
-
Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer
od: Paul, Pulock
Izdano: (2024) -
Impact of treatment size and therapy type in phase II clinical trials of non-small cell lung cancer
od: Rahman, Tasnim
Izdano: (2024) -
Pooled analysis of response rate and overall survival of Tyrosine Kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
od: Karim, Samia Binte
Izdano: (2024) -
Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
od: Flora, Sanzida Alam
Izdano: (2024) -
Molecules associated with the development of lung cancer
od: Rahman, Adree, i dr.
Izdano: (2023)